Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil

Detalhes bibliográficos
Autor(a) principal: Barros, Aluísio J D
Data de Publicação: 2021
Outros Autores: Victora, Cesar G, Menezes, Ana M B, Horta, Bernardo L, Barros, Fernando C, Hartwig, Fernando P, Victora, Gabriel D, Vidaletti, Luis Paulo, Silveira, Mariângela F, Mesenburg, Marilia A, Jacques, Nadège, Struchiner, Cláudio J, Brust, Flávia Roberta, Dall’Agnol, Marinel M, Delamare, Ana Paula Longaray, François, Carlos Henrique R, Ikeda, Maria Letícia R, Pellegrini, Débora C P, Reuter, Cézane Priscila, Silva, Shana G da, Dellagostin, Odir A, Hallal, Pedro C
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista de Saúde Pública
Texto Completo: https://www.revistas.usp.br/rsp/article/view/193411
Resumo: OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.
id USP-23_2cf288fddf1f4c8be24a4c3bfb1f072c
oai_identifier_str oai:revistas.usp.br:article/193411
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, BrazilPopulation-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, BrazilCOVID-19, epidemiology Seroepidemiologic StudiesImmunity, HerdSocioeconomic FactorsHealth SurveysCOVID-19, epidemiologySeroepidemiologic StudiesImmunity, HerdSocioeconomic FactorsHealth SurveysOBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.Universidade de São Paulo. Faculdade de Saúde Pública2021-11-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmlhttps://www.revistas.usp.br/rsp/article/view/19341110.11606/s1518-8787.2021055004075Revista de Saúde Pública; Vol. 55 (2021); 78Revista de Saúde Pública; Vol. 55 (2021); 78Revista de Saúde Pública; v. 55 (2021); 781518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/rsp/article/view/193411/178260https://www.revistas.usp.br/rsp/article/view/193411/178259Copyright (c) 2021 Aluísio J D Barros, Cesar G Victora, Ana M B Menezes, Bernardo L Horta, Fernando C Barros, Fernando P Hartwig, Gabriel D Victora, Luis Paulo Vidaletti, Mariângela F Silveira, Marilia A Mesenburg, Nadège Jacques, Cláudio J Struchiner, Flávia Roberta Brust, Marinel M Dall’Agnol, Ana Paula Longaray Delamare, Carlos Henrique R François, Maria Letícia R Ikeda, Débora C P Pellegrini, Cézane Priscila Reuter, Shana G da Silva, Odir A Dellagostin, Pedro C Hallalhttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBarros, Aluísio J DVictora, Cesar G Menezes, Ana M BHorta, Bernardo L Barros, Fernando C Hartwig, Fernando PVictora, Gabriel D Vidaletti, Luis PauloSilveira, Mariângela FMesenburg, Marilia AJacques, NadègeStruchiner, Cláudio J Brust, Flávia RobertaDall’Agnol, Marinel MDelamare, Ana Paula LongarayFrançois, Carlos Henrique RIkeda, Maria Letícia RPellegrini, Débora C P Reuter, Cézane PriscilaSilva, Shana G daDellagostin, Odir AHallal, Pedro C2021-12-13T18:57:48Zoai:revistas.usp.br:article/193411Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2021-12-13T18:57:48Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
title Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
spellingShingle Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
Barros, Aluísio J D
COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
title_short Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
title_full Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
title_fullStr Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
title_full_unstemmed Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
title_sort Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
author Barros, Aluísio J D
author_facet Barros, Aluísio J D
Victora, Cesar G
Menezes, Ana M B
Horta, Bernardo L
Barros, Fernando C
Hartwig, Fernando P
Victora, Gabriel D
Vidaletti, Luis Paulo
Silveira, Mariângela F
Mesenburg, Marilia A
Jacques, Nadège
Struchiner, Cláudio J
Brust, Flávia Roberta
Dall’Agnol, Marinel M
Delamare, Ana Paula Longaray
François, Carlos Henrique R
Ikeda, Maria Letícia R
Pellegrini, Débora C P
Reuter, Cézane Priscila
Silva, Shana G da
Dellagostin, Odir A
Hallal, Pedro C
author_role author
author2 Victora, Cesar G
Menezes, Ana M B
Horta, Bernardo L
Barros, Fernando C
Hartwig, Fernando P
Victora, Gabriel D
Vidaletti, Luis Paulo
Silveira, Mariângela F
Mesenburg, Marilia A
Jacques, Nadège
Struchiner, Cláudio J
Brust, Flávia Roberta
Dall’Agnol, Marinel M
Delamare, Ana Paula Longaray
François, Carlos Henrique R
Ikeda, Maria Letícia R
Pellegrini, Débora C P
Reuter, Cézane Priscila
Silva, Shana G da
Dellagostin, Odir A
Hallal, Pedro C
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Barros, Aluísio J D
Victora, Cesar G
Menezes, Ana M B
Horta, Bernardo L
Barros, Fernando C
Hartwig, Fernando P
Victora, Gabriel D
Vidaletti, Luis Paulo
Silveira, Mariângela F
Mesenburg, Marilia A
Jacques, Nadège
Struchiner, Cláudio J
Brust, Flávia Roberta
Dall’Agnol, Marinel M
Delamare, Ana Paula Longaray
François, Carlos Henrique R
Ikeda, Maria Letícia R
Pellegrini, Débora C P
Reuter, Cézane Priscila
Silva, Shana G da
Dellagostin, Odir A
Hallal, Pedro C
dc.subject.por.fl_str_mv COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
topic COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
COVID-19, epidemiology
Seroepidemiologic Studies
Immunity, Herd
Socioeconomic Factors
Health Surveys
description OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-22
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rsp/article/view/193411
10.11606/s1518-8787.2021055004075
url https://www.revistas.usp.br/rsp/article/view/193411
identifier_str_mv 10.11606/s1518-8787.2021055004075
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rsp/article/view/193411/178260
https://www.revistas.usp.br/rsp/article/view/193411/178259
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
dc.source.none.fl_str_mv Revista de Saúde Pública; Vol. 55 (2021); 78
Revista de Saúde Pública; Vol. 55 (2021); 78
Revista de Saúde Pública; v. 55 (2021); 78
1518-8787
0034-8910
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1800221802455105536